Update on antiviral therapy for genital herpes infection.
Female; Humans; Male; Infant; Pregnancy; Recurrence; 2-Aminopurine/analogs & derivatives/therapeutic use; Acyclovir/analogs & derivatives/therapeutic use; Antiviral Agents/*therapeutic use; Famciclovir; Valacyclovir; Valine/analogs & derivatives/therapeutic use; Pregnancy Complications; Herpes Genitalis/diagnosis/*drug therapy; Herpes Simplex/transmission; Virus Shedding; Newborn; Infectious Disease Transmission; Infectious/drug therapy; Vertical
For the primary infection of genital herpes, antiviral therapy with acyclovir is the gold standard. For recurrences, there are two options: antiviral treatment of each outbreak as it arises, or suppression of outbreaks with daily oral therapy. Patients tend to prefer the latter because it can decrease the number and severity of outbreaks, but it increases asymptomatic viral shedding and, therefore, the risk of unwittingly transmitting herpes simplex virus to uninfected sexual partners.
Geers T A; Isada C M
Cleveland Clinic journal of medicine
2000
2000-08
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.3949/ccjm.67.8.567" target="_blank" rel="noreferrer noopener">10.3949/ccjm.67.8.567</a>
The treatment of herpes simplex infections: an evidence-based review.
2-Aminopurine/analogs & derivatives/therapeutic use; Acyclovir/analogs & derivatives/therapeutic use; Antiviral Agents/*therapeutic use; Drug Resistance; Evidence-Based Medicine; Famciclovir; Herpes Genitalis/*drug therapy; Herpes Labialis/*drug therapy; Humans; Recurrence; Risk Factors; Valacyclovir; Valine/analogs & derivatives/therapeutic use; Viral
Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference.
Cernik Christina; Gallina Kelly; Brodell Robert T
Archives of Internal Medicine
2008
2008-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1001/archinte.168.11.1137" target="_blank" rel="noreferrer noopener">10.1001/archinte.168.11.1137</a>